Evidence map›Paper›PMID 23106923›Full record

ReviewAddiction (Abingdon, England)2012

Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Hendrée E Jones, Sarah H Heil, Andjela Baewert, Amelia M Arria, Karol Kaltenbach, Peter R Martin, Mara G Coyle, Peter Selby, Susan M Stine, Gabriele Fischer

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Addiction (Abingdon, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 69 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 4 pooled it
22.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03098407 nacompletednot on this mapstarted 2017, after this paper: background citation

A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.

TypeinterventionalSponsorUniversity of PittsburghRan2017 to 2020Enrolled55ConditionsOpioid-Related Disorders, PregnancyArmsBuprenorphine, Methadone
NCT04251208 completednot on this mapstarted 2019, after this paper: background citation

MOms in REcovery (MORE): Defining Optimal Care for Pregnant Women and Infants

TypeobservationalSponsorTrustees of Dartmouth CollegeRan2019 to 2024Enrolled444ConditionsOpioid-Related Disorders, NAS, Substance Use DisordersArmsObservational Study
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 4 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Maintenance agonist treatments for opiate-dependent pregnant women.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Guideline
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

Hendrée E JonesDepartment of Psychiatry and Behavioral Sciences, Hopkins University School of Medicine, Baltimore, MD, USA. hjones18@jhmi.edu
Sarah H Heil
Andjela Baewert
Amelia M Arria
Karol Kaltenbach
Peter R Martin
Mara G Coyle
Peter Selby
Susan M Stine
Gabriele Fischer
Medical University of Vienna · ATBrown University · USJefferson College · USPublic Health Ontario · CARTI International · USUniversity of Maryland, College Park · USUniversity of Vermont · USVanderbilt University · USWayne State University · US

Funding

YOHIMBINE AS A MODEL OF ORTHOSTATIC INTOLERANCEM01RR000095 · NCRR · VANDERBILT UNIVERSITY · PI MAY, JAMES M. · 1985 to 2008
$38.3M
WEIGHT MAINTENANCE AND PSYCHOLOGICAL BENEFITS OF EXERCISEM01RR000109 · NCRR · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI KIRKPATRICK, BETH DIANE · 1985 to 2010
$24.3M
Maternal Opioid Treatment: Human Experimental ResearchR01DA015764 · NIDA · JOHNS HOPKINS UNIVERSITY · PI JONES, HENDREE E · 2004 to 2008
$5.8M
Maternal Opioid Treatment: Human Experimental ResearchR01DA015738 · NIDA · THOMAS JEFFERSON UNIVERSITY · PI KALTENBACH, KAROL A · 2004 to 2008
$3.6M
Maternal Opioid Treatment: Human Experimental ResearchR01DA015713 · NIDA · VANDERBILT UNIVERSITY · PI MARTIN, PETER ROBERT · 2004 to 2008
$2.5M
Maternal Opioid Treatment: Human Experimental ResearchR01DA015832 · NIDA · WAYNE STATE UNIVERSITY · PI STINE, SUSAN M · 2004 to 2009
$2.2M
Maternal Opioid Treatment: Human Experimental ResearchR01DA018410 · NIDA · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI HEIL, SARAH H · 2004 to 2008
$2.2M
Maternal Opioid Treatment: Human ExperimentalR01DA018417 · NIDA · MEDICAL UNIVERSITY OF VIENNA · PI FISCHER, GABRIELE · 2004 to 2008
$1.8M
Maternal Opioid Treatment: Human Experimental ResearchR01DA015778 · NIDA · WOMEN AND INFANTS HOSPITAL-RHODE ISLAND · PI LESTER, BARRY M. · 2004 to 2009
$1.6M
Maternal Opioid Treatment: Human Experimental ResearchR01DA015741 · NIDA · ST. JOSEPH'S HEALTH CENTRE · PI SELBY, PETER L · 2004 to 2008
$643k
NCRR NIH HHS M01 RR000095NCRR NIH HHS M01 RR000109NCRR NIH HHS M01RR00095NCRR NIH HHS M01RR109NIDA NIH HHS R01 DA015713NIDA NIH HHS R01 DA 015738NIDA NIH HHS R01 DA015738NIDA NIH HHS R01 DA 015741NIDA NIH HHS R01 DA015741NIDA NIH HHS R01 DA 015764NIDA NIH HHS R01 DA015764NIDA NIH HHS R01 DA 015778NIDA NIH HHS R01 DA015778NIDA NIH HHS R01 DA015832NIDA NIH HHS R01 DA 017513NIDA NIH HHS R01 DA 018410NIDA NIH HHS R01 DA018410NIDA NIH HHS R01 DA 018417NIDA NIH HHS R01 DA018417NIDA NIH HHS R01 DA 15832
6 · The paper itself

Abstract

aimsThis paper reviews the published literature regarding outcomes following maternal treatment with buprenorphine in five areas: maternal efficacy, fetal effects, neonatal effects, effects on breast milk and longer-term developmental effects.

methodsWithin each outcome area, findings are summarized first for the three randomized clinical trials and then for the 44 non-randomized studies (i.e. prospective studies, case reports and series and retrospective chart reviews), only 28 of which involve independent samples.

resultsResults indicate that maternal treatment with buprenorphine has comparable efficacy to methadone, although difficulties may exist with current buprenorphine induction methods. The available fetal data suggest buprenorphine results in less physiological suppression of fetal heart rate and movements than methadone. Regarding neonatal effects, perhaps the single definitive conclusion is that prenatal buprenorphine treatment results in a clinically significant less severe neonatal abstinence syndrome (NAS) than treatment with methadone. The limited research suggests that, like methadone, buprenorphine is compatible with breastfeeding. Data available thus far suggest that there are no deleterious effects of in utero buprenorphine exposure on infant development.

conclusionsWhile buprenorphine produces a less severe neonatal abstinence syndrome than methadone, both methadone and buprenorphine are important parts of a complete comprehensive treatment approach for opioid-dependent pregnant women.

Indexed as

Opiate Substitution TreatmentSubstance Abuse DetectionBuprenorphineChild DevelopmentFemaleFetusHumansInfant, NewbornLength of StayMethadoneMilk, HumanMorphineNarcotic AntagonistsNeonatal Abstinence SyndromeOpioid-Related DisordersPain ManagementBuprenorphineMethadoneMorphineNarcotic Antagonists

Identifiers

PMID23106923
PMCPMC4506646
OpenAlexW1542715137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.